IP Library Granted Patent US 11,583,514
Granted Patent B2
US 11,583,514 · App. 17/023,681 · Granted Feb 21, 2023

Isoflavonoid compounds and methods for the treatment of cancer

Inventors: George Jeoffreys (Baulkham Hills, AU); Alison Johnson (Drummoyne, AU); Andrew Heaton (Alexandria, AU); Ofir Moreno (Poway, CA)
Assignee: MEI Pharma, Inc.
A61K31/353A61K9/0019A61K9/5161A61K31/337A61K31/555A61K33/243A61K45/06A61K47/40C07D311/58
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,583,514
App. No.
17/023,681
Granted
Feb 21, 2023
Kind
B2
Abstract

Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.

Claims (8)

1. A compound that is d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol provided in at least 90% enantiomeric excess, or a pharmaceutically acceptable salt thereof.

2. A kit comprising a compound that is d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol provided in at least 90% enantiomeric excess, or a pharmaceutically acceptable salt thereof; and a sealable, plastic infusion bag.

3. A method of treating cancer in an individual in need of cancer therapy, the method comprising administering to the individual a compound that is d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol provided in at least 90% enantiomeric excess, or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 , wherein the compound increases or induces sensitivity of the cancer to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.

5. The method of claim 3 , wherein the cancer has lost sensitivity to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.

6. The method of claim 3 , wherein the cancer is bladder cancer, breast cancer, colon cancer, recital cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, or cancers of the brain.

7. The method of claim 3 , wherein the cancer is human breast cancer or ovarian cancer.

8. The method of claim 3 , wherein the method further comprises administering an additional anti-cancer agent selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, epirubicin, cyclophosphamide, capecitabine, 5-fluorouracil, vinorelbine, trastuzumab, and bevacizumab.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2024
From: MEI PHARMA, INC
To: AARDVARK THERAPEUTICS, INC.
Reel/Frame 069422/0065 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2020
From: MORENO, OFIR; JEOFFREYS, GEORGE; JOHNSON, ALISON; HEATON, ANDREW
To: MARSHALL EDWARDS, INC.
Reel/Frame 054488/0681 →
MERGER AND CHANGE OF NAME Recorded Nov 30, 2020
From: MEI PHARMA, INC.; MARSHALL EDWARDS, INC.
To: MEI PHARMA, INC.
Reel/Frame 054488/0990 →
Continuity (5)
Continuation 16129589 · Sep 12, 2018
Continuation 15456182 · Mar 10, 2017
Continuation 13881609
Provisional Application 61408972 · Nov 1, 2010
Related Publication 20210000790A1 · Jan 7, 2021
Cited By (2)
US 12,318,364 US 12,329,739